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Aims: The intravenous application of the chlorite-based drug solutionWF10 is known to improve wound
healing in patients with diabetic foot syndrome. In this retrospective study, we addressed the question,
which effects are caused by this drug in patients with diabetic foot ulcers on the hemoglobin A1c value.
Methods: Patients received ﬁve consecutive daily infusions of WF10. Three patients received a second
cycle of WF10, and one patient a third cycle.
Results: On a group of twelve patients with diabetic foot syndrome, WF10 gradually reduced the HbA1c
values from a high-risk range (9.1 ± 1.6% (76 ± 13 mmol/mol)) into a low-risk range in all patients but
one. These values remain low over at least 8 to 12 weeks after the administration of WF10. This drug
improved also considerably wound healing processes in eleven patients.
Conclusions: The chlorite component of WF10 is known to inactivate eﬃciently free cytotoxic hemoglo-
bin forms that might accumulate in peripheral blood after hemolysis and induces the removal of pre-
damaged red blood cells from circulation. By thesemechanismsWF10 diminished toxic effects of hemolysis,
improved microcirculation and glucose consumption in affected tissues, and prevented, thus, below knee
amputation.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Diabetic foot syndrome (DFS) is a severe pathology of diabetes
mellitus type 1 and 2 and is associated with a 12-month mortality
of 16.7%, which doubles after major amputation [1]. The risk for this
and other common complications of diabetes like retinopathy, ne-
phropathy, cardiovascular disease and others increases with
enhanced values for hemoglobin A1c (HbA1c) [2], an important pa-
rameter for the long-term harm of hyperglycemia. Elevated HbA1c
values are known to decrease the wound healing rate in neuro-
pathic foot wounds and in those with peripheral artery disease [3].
The enhanced, insulin-independent uptake of glucose by eryth-
rocytes favors the glycation of their proteins, impairs the
deformability of these cells, and contributes to an osmotic stress
by conversion of glucose into sorbitol via aldose reductase [4–6].
Hence, the impermeable sorbitol decreases the mechanic fragility
of red blood cells and favors hemolysis [7]. There is a clear rela-
tionship between hemolysis degree and fasting plasma glucose
concentrations as well as the HbA1c value in patients suffering from
diabetes mellitus type 2 [8]. Otherwise, hemolysis diminishes the
bioavailability of nitric monoxide (NO) and decreases, thus, blood
circulation in affected tissues [9]. There is also a general associa-
tion between enhanced glucose concentrations and decreased NO
availability in diabetes [10,11]. In these patients, hemolysis is also
linked to an enhanced thrombotic risk [12,13]. In their blood, the
non-enzymatic modiﬁcation of ﬁbrinogen leads to the formation
of complexes between ﬁbrin ﬁbers and red blood cells and to a
changed morphology of these cells [14].
The chlorite-based drug solution WF10, which is given to pa-
tients in form of an intravenous infusion, has successfully been
applied to improve the clinical outcome in patients with diabetic
foot ulcer syndrome [15,16]. This adjunct therapy to standard di-
abetes treatment signiﬁcantly accelerated thewound healing process
and reduced the rate of foot amputation. However, effects of this
therapy on glucose status and especially on the long-term behav-
ior of the HbA1c value remain unknown.
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To deepen our knowledge about the beneﬁcial action of WF10
in diabetic patients with foot syndrome, we addressed here the ques-
tion whether the administration of WF10 improves besides the
clinical outcome also important parameters of glycemic control. On
twelve DFS patients, WF10 caused a normalization of enhanced
HbA1c values. Follow up of a comparable group of diabetic pa-
tients with DFS, which were subjected to conventional wound care
therapy, revealed no such reduction in HbA1c values [17].
Patients and methods
Patient’s characteristics at baseline
This retrospective study was undertaken fromMarch 2015 to De-
cember 2015 on diabetic patients with foot ulcers at a wound care
clinic, Surgery Department of the General Police Hospital, Bangkok,
Thailand. These patients received WF10 treatment in an attempt
to treat diabetic foot ulcer and prevent below knee amputation (BK).
The data of demographic, coexisting medical conditions, wound
staging, and the glycemic control data before and after treatment
were reviewed.
This study was approved by the ethical committee of the General
Police Hospital, Bangkok, Thailand.
Assessment of wounds
Patient’s ulcer were assessed and classiﬁed into different grades
and stages according toWagner’s Grading System [18]. Grade 0 cor-
responds to intact skin, grade 1 to superﬁcial diabetic foot ulcer, grade
2 to extensive ulcer involving ligament, tendon, joint capsule, or fascia
without abscess or osteomyelitis. The higher wound grades corre-
spond to deep ulcer with abscess or osteomyelitis (grade 3), gangrene
to portion of forefoot (grade 4) or extensive gangrene of foot
(grade 5).
Ulcers were graded as infected or not on the basis of the pres-
ence or absence of purulent discharge together with other local signs
(warmth, erythema, lymphangitis, lymphadenopathy, edema and
pain) and conﬁrmed with swab wound culture. Diagnosis of os-
teomyelitis was made on the basis of radiological ﬁndings.
Determination of parameters of glucose metabolism
Hemoglobin A1c testing was performed by Integra 400 (Roche
Diagnostics, Laval, QC, Canada). Fasting blood glucose level was per-
formed daily by Dextrostix (Dtx) with a Glucocheck meter. Blood
chemistry tests were performed by the Siemens Advia 1800 ana-
lyzer. Complete blood count was performed by Beckman Coulter
hematology analyzer.
Treatment protocol with WF10
Five consecutive infusions of WF10 (referred to as ‘cycle’) at a
dose of 0.3ml/kg bodyweight, diluted in 500ml physiological saline,
were administered to DFS patients in an attempt to prevent BK and
to induce healing of the chronic ulcer. As the primary focus was on
wound healing, in three patients (NP, PS, SA), a second cycle of WF10,
and in one patient (SR) after two cycles at 0.3 ml/kg even a third
cycle at 0.5 ml/kg body weight were deemed clinically beneﬁcial
and consequently administered.
The usually administeredWF10 dose of 0.3ml/kg was lower than
the recommended dose of 0.5 ml/kg. Probably in cases of NP, PS,
and SA a selected dose of 0.5 ml/kg body weight for the ﬁrst cycle
may have lessened the need for another treatment cycle.
Results
Patient’s characteristics during treatment with WF10
This retrospective study was undertaken fromMarch 2015 to De-
cember 2015 on twelve diabetic patients with severe foot ulcers with
gangrened toes and suspected osteomyelitis. These patients re-
ceived WF10 treatment in an attempt to prevent below knee
amputation (BK) at the General Police Hospital, Bangkok, Thai-
land. Baseline characteristics of these patients at hospitalization are
summarized in Table 1.
For eight patients, BK had been recommended by physicians from
transferring hospitals. All patients had been diabetics for an average
of 16 years and were associated with hypertension. Six patients had
cardiovascular disease and three dyslipidemia. Two patients re-
ceived insulin treatment and ten received only oral anti-diabetic
medications prior DFS treatment. Based on this standard of care pa-
tients exhibitedmean fasting glucose values of 202.8mg/dl (107mg/
dl–332 mg/dl) and mean HbA1c levels of 9.1% (6.9%–11.5%) at
baseline. Ten patients had been anemic (hematocrit less than 35%).
Two patients exhibited peripheral occlusive disease symptoms. The
glomerular ﬁltration rate (GFR) for four patients were at or below
60 ml/min. Platelets of eight patients had been elevated.
Upon treatment with WF10, clinically all patients but one (SA)
have shown either complete healing of their wounds or at least im-
provements by two points on theWagner Score. Clinical parameters
of the twelve diabetics, time to complete healing, medications against
diabetes mellitus, and blood transfusions are summarized in Table 2.
Clinically a visible improved blood circulation in affected tissues
could be seen, granulation developed like a manicured lawn. Kidney
function remained stable for at least six months. Elevated plate-
lets became normal.
Alterations in glucose status upon WF10 treatment
In all patients but one (SR), the HbA1c level gradually declined
from high risk levels (9.1 ± 1.6%) to low risk levels of 6. 7 ± 1.4% at
week 4, and 6.2 ± 1.1% at week 8 after ﬁve consecutive daily infu-
sions of WF10 (Table 3). The mean value of 6.8 ± 1.0% at week 12
was also considerably lower than the baseline one, but slightly higher
than the value at week 8. A mean HbA1c value of 7.3 ± 1.5% (n = 7)
was determined at week 16. Statistical analysis applying the un-
paired Student’s t-test revealed a signiﬁcant decrease of HbAc1 data
in comparison to the baseline values with p < 0.001 (week 4, week
8), p < 0.01 (week 12), and p < 0.05 (week 16).
Individual data for alterations of HbA1c values are given in Fig. 1.
HbA1c declined during treatment from high risk into low risk range
for at least eight and up to twelve weeks. Patient SR did not respond
during the ﬁrst two cycles of WF10, but after receiving the recom-
mended dose of 0.5 ml/kg in the third cycle HbA1c declined to 7.3%
at week 12 and further to 6.9% at week 16 (Table 3).
Fasting glucose control improved afterWF10 treatment (Table 3).
Additionally the amount of oral hypoglycemic drugs and insulin re-
quired before and during treatment were gradually reduced and
fasting glucose remained at a level of around 150 mg/dl for at least
eight weeks.
Hematocrit and anemia control
WF10 induced an accelerated splenic clearance of dysfunc-
tional erythrocytes bearing high levels of HbA1c. Patients with the
highest HbA1c levels experienced the highest reduction. Expectedly,
a transient drop in hematocrit values during the infusion period has
been observed accompanied by a compensating erythropoiesis. As
found earlier in healthy individuals and in virus infected patients,
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no sign of hemolysis was observed in this cohort of patients either
[19]. In experimental investigations, fast generation of red blood pre-
cursor cells and erythropoietin generation have been shown after
the ﬁrst WF10 infusion suggesting a strong, compensating eryth-
ropoiesis (data not shown). Over a period of 12 weeks the mean
hematocrit remained stable (Table 3) without further blood trans-
fusions indicating a termination of hemolytic anemia by inactivating
cytotoxic free hemoglobin metabolites.
Table 1
Baseline characteristics of twelve diabetic patients with severe infected foot syndrome at hospitalization before WF10 treatment
Baseline characteristics Range Average ± SD NT PP AS KP NP UA PS CW SR SA NY WW
Sex, male (%) M M M F M M M F M M M M
Age (years) 40–71 55.1 ± 11.1 54 70 40 62 62 59 58 41 71 59 43 42
Duration of diabetes (years) 2–30 13.1 ± 8.4 10 20 8 20 18 30 6 10 20 2 10 3
Nutritional status
Body weight (kg) 50–116 72.6 ± 16.0 65 72 80 50 80 65 70 65 63.5 77 116 68
Height (cm) 152–182 169.7 ± 8.9 165 176 175 152 175 165 163 160 168 182 177 178
Body mass index (kg/m2) 21.5–37.0 25.1 ± 4.1 23.9 23.2 26.1 21.6 26.1 23.9 26.3 25.4 22.5 23.2 37.0 21.5
Serum albumin (g/dL) 2.8–4.6 3.8 ± 0.5 4.1 3.7 3.3 4.6 3.8 2.8 3.7 4.4 4.4 3.3 4.1 3.7
Comorbidities (n)
Hypertension 9 Y Y Y Y – Y Y Y Y – Y –
Nephropathy 1 – – – – Y – – – – – – –
Retinopathy 1 – – – – Y – – – – – – –
Cardiovascular disease 5 Y Y Y Y Y – – – – – – –
Peripheral arterial occlusion disease 2 – – Y Y – – – – – – – –
Dyslipidemia 3 – Y – – – – – Y – – Y –
Diabetic foot ulcer
Ulcer duration (weeks) 6.7 ± 8.4 1 3 24 8 2 24 1 1 4 6 2 4
Previous minor amputation (n) 3 – Y Y Y – – – – – – – –
Previous major amputation (n) 0 – – – – – – – – – – – –
Suggested below knee amputation 8 Y – Y Y Y Y – – – Y Y Y
Wagner wound score 4 3 4 4 3 3 3 1 3 3 3 3
Suspected osteomyelitis (n) 11 Y Y Y Y Y Y Y N Y Y Y Y
Diagnosed ulcer infection (n) 11 Y Y Y Y Y Y Y N Y Y Y Y
Swab culture positive (n) 11 Y Y Y Y Y Y Y N Y Y Y Y
Laboratory ﬁndings
Hemoglobin A1c (%) 6.9–11.5 9.1 ± 1.6 9.7 9.2 11.5 8.9 7.7 6.9 11.1 9.8 7.7 8.4 11.0 7.1
White blood cell count (106/L) 6.6–34.4 13.9 ± 7.4 34.4 13.6 10.6 13.8 6.6 9.6 19.9 9.7 7.7 11.7 15.4 13.3
Hematocrit (%) 26.2–42.9 32.9 ± 4.5 30.1 33.3 26.2 30.8 33.9 33.3 33.0 32.0 30.2 29.5 42.9 39.4
Hemoglobin (g/dL) 8.1–14.4 10.8 ± 1.7 9.8 11.1 8.1 9.7 11.2 10.9 11.2 10.7 9.5 9.7 14.4 12.9
Platelet (106/L) 205–759 433 ± 155 409 382 424 759 280 598 432 245 556 448 456 205
Fasting blood sugar (mg/dL) 107–332 202.8 ± 62.5 187 210 288 229 124 160 196 332 107 220 198 183
Blood urea nitrogen (mg/dL) 10–31 18.4 ± 7.4 19 24 23 31 16 10 12 29 12 22 13 10
Serum creatinine (mg/dL) 0.54–1.78 1.00 ± 0.38 1.11 1.30 0.90 0.75 1.57 1.11 0.71 1.78 0.79 0.86 0.62 0.54
Estimated GFR (eGFR) 43.3–252 98.9 ± 60.5 69.9 53.8 123.5 61.4 55.2 65.9 112.3 43.3 78.0 101.0 252.0 171.0
Blood Tx (unit) before WF10 Rx 2 – – – 2 – – – – 3 – –
Previous anti-DMmedication
Oral anti-diabetic N N Y Y Y Y Y Y Y Y Y N
Previous insulin treatment (n) Y Y N N N N N Y N N N Y
Total dose insulin (U/day) 10 50 – – – – – 35 – – – –
M, male; F, female; Y, yes; N, no.
Table 2
Speciﬁc patient’s characteristics concerning diabetic foot ulcers, anti-diabetic medications and results of WF10 treatment
Characteristics Range Average ± SD NT PP AS KP NP UA PS CW SR SA NY WW
DFS treatment outcome
Wagner score at week 0 1–4 4 3 4 4 3 3 3 1 3 3 3 3
Wagner score at week 12 0–2 NA 0 2 2 0 0 1 0 1 NA 0 0
Time to heal (week) 1–28 11 ± 8 – 14 – 28 1 4 – 6 14 – 10 10
Hemoglobin A1c (%)
At week 0 before WF10 9.7 9.2 11.5 8.9 7.7 6.9 11.1 9.8 7.7 8.4 11.0 7.1
At week 4 5.5 7.8 4.8 6.2 6.5 5.1 6.8 7.4 8.4 5.4 9.5 6.7
At week 8 5.3 5.4 6.4 5.2 5.1 5.5 7.0 8.7 6.9 6.1
At week 12 8.4 5.9 6.4 6.2 6.1 6.1 8.4 7.3 6.5
At week 16 6.2 7.4 8.2 5.9 6.4 10.1 6.9
Blood Tx (unit) before WF10 Rx 2 – – – 2 – – – – 3 – –
Blood Tx (unit) during WF10 Rx 8 – 4 4 - 2 – – – – – –
Previous anti-DMmedication
Oral anti-diabetic N N Y Y Y Y Y Y Y Y Y N
Previous insulin treatment (n) Y Y N N N N N Y N N N Y
Total dose insulin (U/day) 10 50 – – – – – 35 – – – –
Anti-DMmedication during treatment
Oral anti-diabetic N N Y Y Y Y Y Y Y Y Y N
Insulin treatment (n) Y Y Y Y Y Y Y Y Y Y Y Y
Total dose insulin (U/day) 10 50 30 15 10 6 10 35 4 6 3 62
Y, yes; N, no; NA, not analyzed.
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One patient (UA) presented with severe anemia before treat-
ment has shown repeatedly waves of ups (after infusions of two units
RBC to 28% hematocrit) and downs (nearly exactly six weeks later),
but the initial level of 23.5% hematocrit measured at baseline was
never undercut and increased steadily afterWF10 treatment to 25.6%
(December 3, 2015) without further RBC transfusions.
Discussion
In diabetic patients with foot syndrome, the adjuvant therapy
with the chlorite-based drug solution WF10 improves not only the
clinical outcome [15,16], but also as shown in the present study, this
therapy improves signiﬁcantly blood parameters. Intriguingly, there
was a drastic and consistent decline in the HbA1c level into a well-
deﬁned low risk range. Thus, WF10 is remarkably directed toward
basic processes associated with hyperglycemia-mediated patholo-
gies. Remarkably, WF10 administration improved healing of foot
wounds in eleven of the twelve patients. In eight patients, a com-
plete wound healing was observed. In no case, a below knee
amputation was necessary in this patient group.
Hyperglycemia disturbs the redox status and osmotic stability
of red blood cells [4–7,20], favors hemolysis, diminishes the
bioavailability of nitric monoxide, and impairs blood ﬂow param-
eters [8,10,11,21]. Release of hemoglobin from stressed erythrocytes
has long-lasting consequences and is associated with many other
disease scenarios [22,23]. After hemolysis methemoglobin and pro-
toporphyrin IX (also called hemin) are derived from hemoglobin.
As the capacity of the protective plasma proteins haptoglobin and
hemopexin for scavenging and inactivation of these oxidized
heme forms is limited [24], a massive hemolysis is a dangerous
condition to our organism. The hydrophobic hemin, a very toxic com-
ponent, incorporates easily into hydrophobic areas of lipoproteins
and cell membranes [25,26]. In red blood cells, it causes hemolyt-
ic events [27]. Thus, we can hypothesize that in diabetic patients
with severe pathologies such as foot syndrome, not only en-
hanced hyperglycemia, but also the presence of toxic hemolysis
products contributes to the clinical picture.
Chlorite, the active principle of WF10, is known to interact with
heme proteins [28–31]. It inactivates hemoglobin and oxidized he-
moglobin forms [31] that might accumulate in peripheral blood after
hemolysis. Otherwise, WF10 causes a methemoglobin formation in
intact red blood cells [32–35]. Asmethemoglobin formation is counter-
regulated by cellular redox processes [36]WF10 effectswill be favored
in cells with a reduced redox state. Erythrocytes with slightly en-
hanced methemoglobin levels will be removed from circulation by
spleen and liver macrophages [37]. Red blood cells from diabetic in-
dividuals have a screwedmorphology. They are more elongated and
twist around ﬁbrin ﬁbers [14]. Whether this property contributes to
an enhanced removal of pre-damaged red blood cells upon treat-
ment with WF10 should be clariﬁed in ongoing experiments.
From this background, it is not surprising that in some pa-
tients, a strong decline in hematocrit was observed after WF10
administration. The higher HbA1c was at baseline the stronger was
the transient decline in hematocrit. Four of twelve already anemic
patients received compensatory blood transfusion after WF10
administration.
Table 3
Time-dependent alterations in glucose parameters and hematocrit of twelve diabetics with severe foot syndrome after treatment with WF10
Parameter Baseline Week 4 Week 8 Week 12 Week 16
Number of patients considered 12 12 10 9 7
HbA1c (%) 9.1 ± 1.6 6.7 ± 1.4 6.2 ± 1.1 6.8 ± 1.0 7.3 ± 1.5
HbA1c (mmol/mol) 76 ± 13 50 ± 10 44 ± 8 51 ± 8 56 ± 12
Fasting blood glucose (mg/dL) 208 ± 64 170 ± 42 149 ± 22 207 ± 61
Hematocrit (%) 32.9 ± 4.5 30.1 ± 3.8 33.3 ± 8.1 31.1 ± 6.7
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Figure 1. WF10 consistently and drastically reduces HbA1c percentage into normal range. Individual HbA1c values of twelve diabetic DFS patients are given in dependence
on the time after the ﬁrst cycle of WF10 administration. One cycle (5 consecutive infusions on day 1, 2, 3, 4, 5) of WF10 at a dose of 0.3–0.5 ml/kg body mass was admin-
istered to twelve patients, two cycles to three patients (NP, PS, SA), and three cycles to one patient (SR).
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The most intriguing result of this study is the long-lasting strong
decrease in hemoglobin A1c. This parameter serves as an impor-
tant predictor for the long-term harm of hyperglycemia [2]. In
patients with chronic heart failure, increasing HbA1c value is a risk
factor for further cardiovascular complications [38,39]. Enhanced
HbA1c level is also associated with a higher risk for neuropathy, reti-
nopathy, and nephropathy [40,41]. And ﬁnally, HbA1c is a predictor
of healing rate in diabetic wounds [3]. Thus, the decrease in this
parameter is of paramount importance in the therapy of diabetes
complications.
Apparently, the following sequence of events should be respon-
sible for the observed strong decrease of HbA1c. AsWF10 inactivates
serum heme components and induces the removal of pre-damaged
erythrocytes (Fig. 2), these two main sources for hemolytic events
are eliminated or at least are strongly reduced. This improves the
bioavailability of nitricmonoxide and blood circulation, because nitric
monoxide cannot further be utilized by hemolytic hemoglobin
[9,42,43]. Enhanced NO levels also depress the activity of aldose re-
ductase in red blood cells [44,45]. Finally, the enhanced blood supply
to tissues increases the consumption of glucose and reduces thus
the hyperglycemic state.
It is assumed that glycated hemoglobin forms like HbA1c are un-
evenly distributed in the red blood cell population. Higher values
are expected in elder cells and especially already damaged cells.
WF10 induces the predominant removal of those cells from circu-
lation and the formation of novel red blood cells with low level of
glycated proteins. Thus, this decrease in HbA1c should occur within
only few days after WF10 administration. Remarkably, this low level
of HbA1c remains stable over at least eight weeks after therapy in-
dicating a signiﬁcant improvement of physiologic blood ﬂow
parameters and stabilization of glucose utilization. It is still unknown
when hemolysis and osmotic stress ﬂares up again. Currently a stable
HbA1c level in the low risk range of ﬁve months in one patient has
beenmeasured. Thereafter, HbA1c started to rise again, but very slow.
Our data should also be important for other pathologic compli-
cations associated with hyperglycemia developing over years like
chronic kidney disease, retinopathy, coronary arterial disease, and
peripheral arterial disease, referred to asmetabolic syndrome or syn-
drome X [46–49]. Also, in these cases, the generation of toxic
metabolites due to a smoldering hemolysis will contribute to disease
progression. It is therefore a promising approach to focus on red
blood cells as a therapeutic target having a relative short lifetime
with the objective to interrupt the vicious cycle of hemolysis and
to get rid of those cytotoxic hemoglobin metabolites.
Conclusion
The preliminary ﬁndings in this cohort of hyperglycemic pa-
tients presented with severe ulcers with gangrened toes and
osteomyelitis and suggested for below knee amputation (BK) have
shown besides good clinical outcome an improved glycemic control
and a dramatic and consistent reduction in HbA1c, a predictor for
death and micro-vascular complications in diabetics, after ﬁve in-
fusions of WF10. Transient anemia during infusion could bemanaged
by compensatory blood transfusions. Hemolysis was controlled by
WF10-mediated inactivation of cytotoxic free hemoglobin prod-
ucts and removal of dysfunctional erythrocytes prone to a smoldering
hemolysis. This therapy improved signiﬁcantly blood circulation in
affected tissues and blood parameters signaling a better control and
consumption of glucose. Further studies are warranted to verify this
approach.
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